Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
Cardiol Therapeutics has nominated Dr. Timothy Garnett to its Board of Directors, bringing over 30 years of pharmaceutical industry expertise. Dr. Garnett, the former Chief Medical Officer of Eli Lilly (2008-2021), will stand for election at the Company's 2025 Annual General Meeting on May 28.
During his tenure at Eli Lilly, Dr. Garnett led successful therapeutic developments in:
- Women's health
- Endocrinology
- Neuroscience
The nomination coincides with Cardiol's milestone of initiating patient enrollment in their pivotal Phase III MAVERIC trial. Dr. Garnett currently serves as Chair of Ophirex, Director of MapLight Therapeutics, and holds advisory roles at Cambridge Innovation Capital and Recode Health Ventures. His expertise in clinical development and regulatory approval processes aligns with Cardiol's mission to develop anti-inflammatory and anti-fibrotic therapies for heart disease treatment.
Cardiol Therapeutics ha nominato il dottor Timothy Garnett nel suo Consiglio di Amministrazione, portando oltre 30 anni di esperienza nell'industria farmaceutica. Il dottor Garnett, ex Chief Medical Officer di Eli Lilly (2008-2021), si candiderà alle elezioni durante l'Assemblea Annuale della Società del 2025, prevista per il 28 maggio.
Durante il suo incarico in Eli Lilly, il dottor Garnett ha guidato con successo sviluppi terapeutici in:
- Salute femminile
- Endocrinologia
- Neuroscienze
La nomina coincide con il traguardo di Cardiol di iniziare il reclutamento dei pazienti per il loro cruciale studio di Fase III MAVERIC. Attualmente, il dottor Garnett è Presidente di Ophirex, Direttore di MapLight Therapeutics e ricopre ruoli consulenziali presso Cambridge Innovation Capital e Recode Health Ventures. La sua competenza nello sviluppo clinico e nei processi di approvazione regolatoria si allinea con la missione di Cardiol di sviluppare terapie anti-infiammatorie e anti-fibrotiche per il trattamento delle malattie cardiache.
Cardiol Therapeutics ha designado al Dr. Timothy Garnett para su Junta Directiva, aportando más de 30 años de experiencia en la industria farmacéutica. El Dr. Garnett, ex Director Médico de Eli Lilly (2008-2021), se postulará para elección en la Junta General Anual de la Compañía en 2025, el 28 de mayo.
Durante su etapa en Eli Lilly, el Dr. Garnett lideró desarrollos terapéuticos exitosos en:
- Salud femenina
- Endocrinología
- Neurociencia
La nominación coincide con el hito de Cardiol de iniciar la inscripción de pacientes en su crucial ensayo de Fase III MAVERIC. Actualmente, el Dr. Garnett es presidente de Ophirex, director de MapLight Therapeutics y asesora a Cambridge Innovation Capital y Recode Health Ventures. Su experiencia en desarrollo clínico y procesos regulatorios está alineada con la misión de Cardiol de desarrollar terapias antiinflamatorias y antifibróticas para el tratamiento de enfermedades cardíacas.
Cardiol Therapeutics는 제약 산업에서 30년 이상의 경험을 가진 Dr. Timothy Garnett를 이사회 이사로 임명했습니다. Dr. Garnett는 Eli Lilly의 전 최고 의학 책임자(2008-2021)로, 2025년 5월 28일 회사 연례 총회에서 이사 선출에 출마할 예정입니다.
Eli Lilly 재직 기간 동안 Dr. Garnett는 다음 분야에서 성공적인 치료 개발을 이끌었습니다:
- 여성 건강
- 내분비학
- 신경과학
이번 임명은 Cardiol이 중요한 3상 MAVERIC 시험에서 환자 등록을 시작하는 중요한 시점과 맞물립니다. 현재 Dr. Garnett는 Ophirex 의장, MapLight Therapeutics 이사이며 Cambridge Innovation Capital과 Recode Health Ventures의 자문 역할을 맡고 있습니다. 임상 개발 및 규제 승인 과정에 대한 그의 전문성은 심장 질환 치료를 위한 항염증 및 항섬유화 치료제 개발이라는 Cardiol의 목표와 부합합니다.
Cardiol Therapeutics a nommé le Dr Timothy Garnett au sein de son conseil d'administration, apportant plus de 30 ans d'expérience dans l'industrie pharmaceutique. Le Dr Garnett, ancien directeur médical de Eli Lilly (2008-2021), se présentera aux élections lors de l'assemblée générale annuelle de la société en 2025, le 28 mai.
Durant son mandat chez Eli Lilly, le Dr Garnett a dirigé avec succès des développements thérapeutiques dans les domaines suivants :
- Santé des femmes
- Endocrinologie
- Neurosciences
Cette nomination coïncide avec l'étape importante pour Cardiol qui débute le recrutement des patients pour son essai pivot de Phase III MAVERIC. Le Dr Garnett est actuellement président d'Ophirex, administrateur de MapLight Therapeutics et occupe des fonctions consultatives auprès de Cambridge Innovation Capital et Recode Health Ventures. Son expertise en développement clinique et en approbation réglementaire est en adéquation avec la mission de Cardiol de développer des thérapies anti-inflammatoires et anti-fibrotiques pour le traitement des maladies cardiaques.
Cardiol Therapeutics hat Dr. Timothy Garnett in seinen Vorstand berufen, der über 30 Jahre Erfahrung in der Pharmaindustrie mitbringt. Dr. Garnett, ehemaliger Chief Medical Officer von Eli Lilly (2008-2021), wird sich bei der Hauptversammlung des Unternehmens 2025 am 28. Mai zur Wahl stellen.
Während seiner Zeit bei Eli Lilly leitete Dr. Garnett erfolgreiche therapeutische Entwicklungen in den Bereichen:
- Frauenheilkunde
- Endokrinologie
- Neurowissenschaften
Die Ernennung fällt mit dem Meilenstein von Cardiol zusammen, mit der Patientenaufnahme in ihrer entscheidenden Phase-III-Studie MAVERIC zu beginnen. Dr. Garnett ist derzeit Vorsitzender von Ophirex, Direktor von MapLight Therapeutics und berät Cambridge Innovation Capital sowie Recode Health Ventures. Seine Expertise in klinischer Entwicklung und Zulassungsverfahren passt zur Mission von Cardiol, entzündungshemmende und antifibrotische Therapien zur Behandlung von Herzkrankheiten zu entwickeln.
- Nomination of former Eli Lilly Chief Medical Officer with 30+ years pharmaceutical industry experience
- Dr. Garnett's proven track record in guiding multiple drugs through regulatory approval and commercial launch
- Currently in Phase III MAVERIC trial with active patient enrollment
- Strategic addition to board during crucial clinical development phase
- None.
Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience
Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D., has been nominated to stand for election to the Company's Board of Directors at its 2025 Annual General Meeting of shareholders to be held on May 28, 2025.
Dr. Garnett is a distinguished pharmaceutical industry executive with over 30 years' experience, including two decades at Eli Lilly and Company, where he served as Chief Medical Officer from 2008 until his retirement in 2021. During his tenure at Eli Lilly, he led the successful development of therapeutics in women's health, endocrinology, and neuroscience, resulting in multiple global commercial launches. Dr. Garnett has played a key role in the successful development of numerous drugs across both early- and late-stage clinical development. He has broad experience leading clinical development, portfolio management, medical affairs, regulatory strategy, and safety functional areas, and has a strategic understanding of the evolving metabolic therapy landscape.
"We are pleased to nominate Dr. Garnett for election to our Board of Directors, as we mark a significant milestone with the recent initiation of patient enrollment in our pivotal Phase III MAVERIC trial," stated Guillermo Torre-Amione, M.D., Ph.D., Chair of Cardiol Therapeutics. "Dr. Garnett brings a wealth of industry experience and strategic vision, along with exceptional expertise in clinical development. His proven track record in guiding several drugs through regulatory approval and successful commercial launch will be instrumental in achieving our goal of making a meaningful difference for people living with underserved heart disease."
Dr. Garnett currently serves as Chair of Ophirex and a Director of MapLight Therapeutics. In addition, he is a member of the Advisory Panel of Cambridge Innovation Capital and an equity partner at Recode Health Ventures LLC. Dr. Garnett holds a Bachelor of Medicine and Bachelor of Surgery (MBBS) from St. George's, University of London. He is a Fellow of both the Faculty of Pharmaceutical Medicine (FFPM), and the Royal College of Obstetricians and Gynaecologists (FRCOG).
About Cardiol Therapeutics
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.
Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration ("US FDA") to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The ongoing ARCHER trial (NCT05180240) is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis.
Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure - a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding
For more information about Cardiol Therapeutics, please visit cardiolrx.com.
Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward-looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx, and the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation of cannabidiol intended for use in heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian Securities Administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Supplement, the accompanying Base Prospectus and the documents incorporated by reference therein.
For further information, please contact:
Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250087
FAQ
Who is Dr. Timothy Garnett joining Cardiol Therapeutics (CRDL) and what is his background?
When will Cardiol Therapeutics (CRDL) hold its 2025 Annual General Meeting?
What is Cardiol Therapeutics' (CRDL) current clinical trial status?
What are Dr. Garnett's current roles besides the Cardiol (CRDL) board nomination?
How will Dr. Garnett's experience benefit Cardiol Therapeutics (CRDL)?
